{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003489","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.970017+00:00","generated_at":"2026-06-07T03:00:48.452347+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Catalyst Pharmaceuticals prices public offering of 10M shares at $15.00, raising $150M gross","bullets":["Offering of 10,000,000 shares at $15.00 each, gross proceeds $150M; net proceeds ~$140.1M.","Underwriters have 30-day option to purchase up to an additional 1.5M shares.","Net proceeds to fund potential acquisition of new product candidates and general corporate purposes.","Offering expected to close on January 9, 2024; underwriters include BofA Securities and Citigroup."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003489","json":"https://secwatch.observer/filing/0001193125-24-003489.json","markdown":"https://secwatch.observer/filing/0001193125-24-003489.md","text":"https://secwatch.observer/filing/0001193125-24-003489.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312524003489/0001193125-24-003489-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312524003489/d149661d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:00:48.452347+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"46e10de295121ec3178bd155f3357ba9666acd8e","claim":"CATALYST PHARMACEUTICALS, INC. entered into Underwriting Agreement with BofA Securities, Inc. and Citigroup Global Markets, Inc., as representatives of the underwriters named in Schedule A to the Underwriting Agreement valued at 10,000,000 shares of the Company’s common stock, par value $0.001 per share, at a public offering pr (effective 2024-01-04).","evidence_excerpt":"On January 4, 2024, Catalyst Pharmaceuticals, Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with BofA Securities, Inc. and Citigroup Global Markets, Inc., as representatives of the underwriters named in Schedule A to the Underwriting Agreement (collectively, the “ Underwriters ”), relating to the public offering, issuance and sale (the “ Offering ”) by the Company of 10,000,000 shares of the Company’s common stock, par value $0.001 per share (the “ Shares ”), at a public offering price of $15.00 per share, less underwriting discounts","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369568/000119312524003489/0001193125-24-003489-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"BofA Securities, Inc. and Citigroup Global Markets, Inc., as representatives of the underwriters named in Schedule A to the Underwriting Agreement"},{"label":"Value","value":"10,000,000 shares of the Company’s common stock, par value $0.001 per share, at a public offering pr"},{"label":"Effective","value":"2024-01-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}